Biden’s $35 Billion Proposal: Medicare and Medicaid to Cover Weight-Loss Injectables for Obese Americans

Biden Administration’s Proposal for Weight-Loss Drugs

Millions of obese Americans could gain access to weight-loss injectables if a $35 billion proposal from the Biden administration is approved by President-elect Trump. This rule from the Health and Human Services Department would require Medicare and Medicaid to cover drugs like Wegovy and Zepbound.

Mechanism of Action

These weight-loss drugs, known as GLP-1s, mimic a hormone that controls appetite, helping people feel full after eating. In clinical trials, participants using Wegovy or Mounjaro lost between 15% to 22% of their body weight, translating to significant pounds shed for many. Though typically expensive, priced above $1,000 monthly, these drugs have been hard to access without insurance coverage.

Impact on Coverage

The proposed rule aims to modify existing federal laws. It could open coverage for around 3.5 million Medicare and 4 million Medicaid recipients currently considered obese, although estimates suggest that 28 million Medicaid participants might qualify. The total cost of the proposal could reach $35 billion over the next ten years.

Political Support and Opposition

While many Americans support Medicare covering these drugs, the proposal’s fate remains uncertain under Trump’s administration. Trump has appointed Robert F. Kennedy Jr., a critic of the drugs, to lead HHS. Despite mixed support within Trump’s circle, some officials, like Dr. Mehmet Oz, acknowledge the potential benefits of these medications.

Reactions from Lawmakers

Some lawmakers express enthusiasm for the rule, viewing it as a way to promote health and reduce long-term costs. Representative Brad Wenstrup praised the proposal, while Senator Bernie Sanders cautioned that without price regulation, Medicare costs could rise significantly.

Concerns from Medical Professionals

Doctors recognize the efficacy of these drugs but emphasize the importance of a comprehensive approach to obesity treatment. They advocate for research into the causes of obesity and emphasize healthy food and exercise. Concerns also arise regarding potential side effects, especially for older patients.

In summary, the Biden proposal could change how obesity is treated in the U.S., making effective medications available to millions, pending approval from the new administration.